Antion Biosciences
Geneva
About Antion Biosciences
Antion Biosciences SA is a cell and gene engineering biotechnology company based in Geneva (Switzerland). It develops off-the-shelf therapies for the treatment of diseases with significant unmet medical needs. Antion’s proprietary technology allows for a modular and tunable approach to multiplex engineering of therapeutic cells. We have made a strategic shift to re-purpose our miCAR19 developments for autoimmune disease, building upon the recently shown in vivo proof-of-concept data with our lead product, miCAR7. Antion is one of the few players with an allogeneic solution. By leveraging its multiplex engineering technology, it has the potential to deliver a best-in-class product for B-cell-driven autoimmune disease. Significant preclinical progress has already been made, with the following value inflection point being proof-of-concept in humans.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $7.1M
- Last round: Debt Financing (Apr 2024)
- Website: antionbio.com
- Phone: +41 (0)22 310 63 70
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/antion-biosciences-154473 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.